Virtuoso Epigenomic Platform
Empowering Drug Development through Epigenomics
The Virtuoso epigenomic platform, by ClearNote Health, measures active disease biology from drug discovery through development, including dynamic insights into therapy response and resistance — all through a simple blood draw.
Virtuoso Epigenomics Platform: Revealing Biological Changes in Plasma
Traditional drug development processes are plagued by challenges such as high costs, limited tissue availability, and low success rates. To address these challenges, ClearNote Health introduced the Virtuoso Epigenomics Platform, a groundbreaking whole genome sequencing and 5hmC enrichment solution designed to revolutionize translational research by revealing active disease biology to empower drug discovery and development.
The Virtuoso Platform represents a paradigm shift in drug development, offering non-invasive testing, longitudinal research capabilities, and individualized patient epigenomics to reveal critical biological changes in plasma. By leveraging these capabilities, the Virtuoso Platform accelerates the pace of drug development, enhances patient safety, and transforms the future of healthcare.
From Blood To Breakthrough
Integrated 5hmC-Profile Analysis for Enhanced Clinical Insight
.
Partner with the epigenomic experts to empower your oncology drug development
Virtuoso provides clinical insights for BioPharma Partners